Table 3.
Efficacy and safety of combination treatment with RLT.
| Combination Partner |
ORR (%) | OS (Months) |
PFS (Months) |
SAE (%) | Reference |
|---|---|---|---|---|---|
| SSA | 37 | NR | 48 | 3% hepatoxicity | [52,53,65] |
| Capecitabine | 24–30 | NR | 31 | 15% hematotoxicity | [87,88] |
| CAPTEM | 53–70 | NR | 22–48 | 6% hematotoxicity | [76,77,78] |
| 5-FU | 25 | NR | - | - | [89] |
| Everolimus | 44 | NR | 63 at 2 years | 100% hematotoxicity | [79] |
| EBRT | 0 | NR | 108 | - | [90] |
| Liver Embolization | |||||
| (90Y) | 16 | 42–68 | - | 50% liver enzyme elevation | [83,84,91] |
| (166Ho) | 43 | - | 10% abdominal pain | ||
| Dual RLT (177Lu/90Y) | 42 | 66–127 | - | 2% MDS | [63,85,86] |
| (177Lu/225Ac) | - | 7% hematotoxicity | |||
| MIBG (131I) | 0 | - | 33% thrombocytopenia | [92] |